Sagility Q1 FY27 Earnings Call Transcript Released
Sagility Limited reported Q1 FY27 revenue of ₹19,635 million (27.6% YoY growth). Adjusted EBITDA was ₹4,716 million (24% margin), and Adjusted PAT was ₹2,697 million (13.7% margin). The company reiterated its FY27 guidance for low double-digit organic growth and maintained EBITDA margin guidance of 24-25%. The acquisition of CareSeed was highlighted as strengthening quality capabilities.
The announcement is a transcript of an earnings call, which provides detailed financial performance and outlook. While positive, it does not introduce entirely new strategic initiatives or major market-moving events beyond the ongoing financial reporting cycle.
The company reported strong year-on-year growth in revenue, EBITDA, and PAT, and reiterated positive financial guidance for the full year, indicating a favorable financial performance.
Sagility Limited has released the transcript of its Investors Call held on July 21, 2026, to discuss the unaudited financial results for the quarter ended June 30, 2026. The call featured management, including Ramesh Gopalan (MD & Group CEO) and Srinivas Rathnam Mattapalli (EVP & Group CFO), discussing the company's performance and market context.
Ramesh Gopalan highlighted a strong start to FY2027, with revenue for the quarter at ₹19,635 million ($207.8 million), representing 27.6% year-on-year growth. Adjusted EBITDA stood at ₹4,716 million ($49.9 million) with a 24% margin, and Adjusted PAT increased to ₹2,697 million ($28.6 million) with a 13.7% margin. He also discussed the strategic direction, focusing on integrated, outcome-driven frameworks, and the successful acquisition of CareSeed, which strengthens capabilities in quality reporting and expands market reach.
Srinivas Mattapalli provided further financial details, noting that excluding CareSeed, revenue grew 27.3% year-on-year. He addressed the impact of seasonalities, minimum wage revisions, and salary increases on margins, while also highlighting strong operating cash flow and DSO improvements. The company reiterated its FY2027 guidance of low double-digit organic growth in constant currency and maintained its EBITDA margin guidance of 24% to 25% despite absorbing increased wage costs.
The Q&A session covered topics such as the impact of minimum wage hikes, strategies for mitigating these costs, revenue growth drivers, and potential future acquisitions in clinical services and technology. Management expressed confidence in their ability to deliver sustainable growth and maintain healthy profitability.
What to do with a filing like this
SAGILITY LIMITED filed this with the NSE as a statutory disclosure, categorised under concall transcript released. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by SAGILITY LIMITED. Read the original for the full detail.